Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more
Design Therapeutics Inc (DSGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.056x
Based on the latest financial reports, Design Therapeutics Inc (DSGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.16 Million) by net assets ($199.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Design Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Design Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Design Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Jinling Sports Equipment Co Ltd
SHE:300651
|
0.053x |
|
PT. Indika Energy Tbk
F:I41
|
N/A |
|
Rejlers AB (publ)
ST:REJL-B
|
0.055x |
|
Cohen Circle Acquisition Corp. I
NASDAQ:CCIRU
|
-0.003x |
|
5N Plus Inc
PINK:FPLSF
|
0.092x |
|
Guangzhou Jiacheng
SHG:603535
|
0.031x |
|
FibraHotel
MX:FIHO12
|
0.027x |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
0.019x |
Annual Cash Flow Conversion Efficiency for Design Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Design Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $242.10 Million | $-43.10 Million | -0.178x | +15.57% |
| 2023-12-31 | $277.69 Million | $-58.56 Million | -0.211x | -34.51% |
| 2022-12-31 | $327.31 Million | $-51.32 Million | -0.157x | -103.94% |
| 2021-12-31 | $382.13 Million | $-29.38 Million | -0.077x | -110.03% |
| 2020-12-31 | $-11.31 Million | $-8.67 Million | 0.766x | +1907.43% |
| 2019-12-31 | $-3.64 Million | $-139.00K | 0.038x | -- |